Clinical trials: Mature T-cell Lymphoma
Peripheral T-cell Lymphoma
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
This is a single-arm, single-center Phase II clinical trial for patients with relapsed or refractory Peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04052659
- Testing
- Sintilimab, Chidamide, Azacidine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
T Cell Lymphoma, T-cell Leukemia
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
This is a multicenter phase I clinical study evaluating the safety, tolerability, and efficacy of LCAR-T2C cell agents targeting CD4 in patients with relapsed/refractory CD4-positive T lymphocytic tumors.
- Trial name
- NCT04973527
- Testing
- Efficacy of LCAR-T2C CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Beijing Boren Hospital
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT06855823
- Testing
- Golicitinib combined with Pomadomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the…
- Trial name
- NCT07615283
- Testing
- Adebrelimab & SHR2554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Chronic Myeloproliferative Disorders, Leukemia
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006379
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Cutaneous T-cell Lymphoma
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
This study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma (CTCL) that has relapsed (returned after…
- Trial name
- NCT00554827
- Testing
- Vitamin B12, Folic Acid, Pralatrexate
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed/Refractory Peripheral T Cell Lymphoma
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
- Trial name
- NCT06702605
- Testing
- XNW5004 tablets
- Volunteers
- 50 people
- Sponsor
- Evopoint Biosciences Inc.
Lymphoma
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody and P-GemOx in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573151
- Testing
- Selinexor, anti-PD-1 antibody and P-GemOx
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Peripheral T Cell Lymphoma
Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodgkin's lymphoma (HL) and…
- Trial name
- NCT01470066
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Chonnam National University Hospital
Peripheral T Cell Lymphoma
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
This is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity.
- Trial name
- NCT06511895
- Testing
- AZD4205
- Where
- 19 sites in China
- Volunteers
- 57 people
- Sponsor
- Dizal Pharmaceuticals
Lymphatic Diseases
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of Brentuximab Vedotin (BV) as a single agent in relapsed/refractory CD30+ PTCL patients.
- Trial name
- NCT02497131
- Testing
- Brentuximab Vedotin
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Lymphoma, Small Intestine Cancer
BMS-247550 in Treating Patients With Advanced Cancers
Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006221
- Testing
- ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous T-cell Lymphoma
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia.
- Trial name
- NCT00106431
- Testing
- romidepsin (depsipeptide, FK228)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- Celgene
T-cell Lymphoma
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
BCD (Bendamustine, carboplatin and dexamethasone)chemotherapy regimen is proposed as the salvage treatment for relapsed or refractory PTCLs in this study protocol, which would be expected to show more promising clinical outcomes…
- Trial name
- NCT02424045
- Testing
- BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Lymphoma, T-Cell
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene.
- Trial name
- NCT03703375
- Testing
- Azacitidine, Romidepsin, Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 93 people
- Sponsor
- Celgene
Lymphoma
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Combinations of biological substances in alefacept may be able to carry cancer-killing substances directly to cancer cells.
- Trial name
- NCT00438802
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.